Combination CD200R/PD-1 blockade in a humanised mouse model.
CD200R
PD-1
cancer immunotherapy
monoclonal antibody
nivolumab
Journal
Immunotherapy advances
ISSN: 2732-4303
Titre abrégé: Immunother Adv
Pays: England
ID NLM: 101776979
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
12
2022
accepted:
29
03
2023
medline:
21
4
2023
pubmed:
21
4
2023
entrez:
21
04
2023
Statut:
epublish
Résumé
There is an increasing number of immune-checkpoint inhibitors being developed and approved for cancer immunotherapy. Most of the new therapies aim to reactivate tumour-infiltrating T cells, which are responsible for tumour killing. However, in many tumours, the most abundant infiltrating immune cells are macrophages and myeloid cells, which can be tumour-promoting as well as tumouricidal. CD200R was initially identified as a myeloid-restricted, inhibitory immune receptor, but was subsequently also found to be expressed within the lymphoid lineage. Using a mouse model humanised for CD200R and PD-1, we investigated the potential of a combination therapy comprising nivolumab, a clinically approved PD-1 blocking antibody, and OX108, a CD200R antagonist. We produced nivolumab as a murine IgG1 antibody and validated its binding activity
Identifiants
pubmed: 37082107
doi: 10.1093/immadv/ltad006
pii: ltad006
pmc: PMC10112683
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ltad006Subventions
Organisme : Wellcome Trust
ID : 207547/Z/17/Z
Pays : United Kingdom
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Immunology.
Déclaration de conflit d'intérêts
The authors declare that they have no competing financial interests.
Références
J Immunol. 2004 Dec 1;173(11):6786-93
pubmed: 15557172
Curr Allergy Asthma Rep. 2016 Jan;16(1):7
pubmed: 26742760
PLoS One. 2019 Jan 17;14(1):e0210796
pubmed: 30653571
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Innate Immun. 2019 Jan;25(1):46-59
pubmed: 30782043
J Immunother Cancer. 2022 Jan;10(1):
pubmed: 35017153
MAbs. 2022 Jan-Dec;14(1):2088454
pubmed: 35924382
Biochem Biophys Res Commun. 2008 Feb 1;366(1):117-22
pubmed: 18060862
Cancer Cell. 2015 Sep 14;28(3):285-95
pubmed: 26373277
Nat Commun. 2021 May 5;12(1):2526
pubmed: 33953190
J Immunol. 2003 Sep 15;171(6):3034-46
pubmed: 12960329
Oncogene. 2012 Jun 14;31(24):2979-88
pubmed: 22020332
J Immunol. 2008 Jan 15;180(2):699-705
pubmed: 18178807
Sci Rep. 2013 Oct 30;3:3072
pubmed: 24170042
Science. 2000 Dec 1;290(5497):1768-71
pubmed: 11099416
Nat Immunol. 2008 Sep;9(9):1074-83
pubmed: 18660812
Nature. 2014 Nov 6;515(7525):134-7
pubmed: 25156255
Eur J Immunol. 2004 Jun;34(6):1688-94
pubmed: 15162439
Cancer Cell. 2016 Aug 8;30(2):324-336
pubmed: 27424807
Anticancer Res. 2020 Oct;40(10):5329-5341
pubmed: 32988851
Biochem Biophys Res Commun. 2020 Jun 18;527(1):213-217
pubmed: 32446369
Front Cell Dev Biol. 2021 Oct 08;9:739816
pubmed: 34692697
Leukemia. 2015 Sep;29(9):1952-4
pubmed: 25748687
J Immunol. 2009 Oct 15;183(8):4879-86
pubmed: 19786546
J Immunol. 2006 Jan 1;176(1):191-9
pubmed: 16365410
J Immunol. 2004 Sep 15;173(6):3748-54
pubmed: 15356121
Cancer Res. 2010 Apr 1;70(7):2962-72
pubmed: 20332223
Elife. 2020 Jan 28;9:
pubmed: 31990272
Eur J Immunol. 2010 Sep;40(9):2569-79
pubmed: 20662098
J Immunol. 2008 Nov 1;181(9):6664-9
pubmed: 18941257
J Immunol. 2005 Oct 1;175(7):4441-9
pubmed: 16177086
Protein Eng. 2003 Apr;16(4):243-5
pubmed: 12736366
Leukemia. 2007 Mar;21(3):566-8
pubmed: 17252007
Oncotarget. 2017 May 4;8(39):64892-64906
pubmed: 29029399
J Immunol. 2009 Aug 1;183(3):1990-6
pubmed: 19587022
J Immunother Cancer. 2014 Dec 16;2(1):46
pubmed: 25598973
iScience. 2020 Dec 24;24(1):101960
pubmed: 33437940
J Biol Chem. 2013 Apr 26;288(17):11771-85
pubmed: 23417675
J Virol. 2012 Jun;86(11):6246-57
pubmed: 22491458
J Clin Oncol. 2022 Sep 10;40(26):3065-3076
pubmed: 35442766
Immunology. 2001 Feb;102(2):173-9
pubmed: 11260322
Front Immunol. 2019 Nov 28;10:2746
pubmed: 31849950
Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11103-8
pubmed: 23690610
Cell Rep. 2019 Aug 20;28(8):2156-2168.e5
pubmed: 31433989
Leuk Res. 2009 Mar;33(3):460-4
pubmed: 18838168
J Immunother Cancer. 2019 Aug 23;7(1):227
pubmed: 31443741
PLoS One. 2012;7(2):e31442
pubmed: 22319630
Oncogene. 2015 Jul;34(29):3860-70
pubmed: 25263452